Introduction {#Sec1}
============

Obesity is increasing in prevalence; global estimates believe that the number of individuals who are either overweight or obese is around 2.1 billion \[[@CR1]\]. The metabolic complications of obesity (diabetes, hyperlipidemia, and hypertension) are well recognized \[[@CR2]--[@CR4]\]. Obesity is also shown, however, to correlate with an increase in gastroesophageal reflux disease (GERD)-related disorders, including Barrett's esophagus (BE) and esophageal carcinoma \[[@CR5]\]. The rising obesity epidemic is therefore presumed to contribute to the increased incidence in GERD-related disorders \[[@CR5]\].

Abdominal obesity and body mass index (BMI) are proven risk factors for increasing esophageal reflux \[[@CR5], [@CR6]\]. Reflux of gastric contents and bile into the esophagus induces inflammation that can result in metaplasia and dysplasia of the esophageal epithelium \[[@CR7]\]. Previous analysis of factors associated with GERD-related disorders additionally identifies genetic, demographic, behavioral, and co-morbid factors that increase the propensity of developing this spectrum of diseases \[[@CR8], [@CR9]\]. These however have not been studied within a uniquely obese population to elucidate which of these factors, if any, increase the progression of reflux-related disease and symptomology.

Proton pump inhibitors (PPIs) are an effective treatment for symptomatic relief from reflux esophagitis \[[@CR10]\]. PPIs have also been demonstrated to effectively reduce the duration of esophageal acid exposure in obese patients, across all examined obesity classes \[[@CR11]\]. This was confirmed clinically as PPIs negate any propensity to show progressive esophageal erosion or GERD. Despite this, it is still known that obese patients on PPI therapy still progress to develop GERD-related disorders \[[@CR12]\].

The aim of this study was to perform a population analysis of obese patients on PPIs to elucidate any risk factors that increase the propensity to develop Barrett's esophagus or esophageal carcinoma.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

A population-based case-control study of obese patients (BMI ≥ 30 kg/m^2^) who received PPI therapy was conducted utilizing the Clinical Practice Research Datalink (CPRD) in the UK. An analysis was conducted to identify potential factors that might influence the progression of this group of patients towards GERD, BE, or esophageal carcinoma.

The Clinical Practice Research Datalink is the largest clinical database in the UK, derived from a population of 8.5% of general practices. Campbell et al. have previously demonstrated the CPRD to be a representative sample of the national population \[[@CR13]\]. The CPRD has also shown equivalent incident rates to other epidemiological analyses of the UK's general population \[[@CR14]\]. A median of 89% of reported cases within the CPRD are also confirmed on internal or external validation \[[@CR14]\]. The data extraction collected patient visits between 1987 and 2017. Patients were followed up longitudinally until last appointment prior to data extraction, change of practice, or death.

Patient and Data Selection {#Sec4}
--------------------------

Patients were identified from the CPRD via clinical codes that were determined using a consensus approach. The initial step of this required the generation of definitions for the disease of interest. This was defined as patients with BMI ≥ 30 kg/m^2^ and had received PPI therapy by all authors. Subsequently, a list of clinical codes was generated between two authors (S.E. and O.M.). A comprehensive collection of synonyms was created for each variable. These were cross-matched against "medcodes" and descriptions provided by the CPRD for every disease, medication, and symptom using Stata (StataCorp 14, TX, USA). Data was extracted and cleaned in a systematic manner from the CPRD. Incidence of three clinical end points was isolated: GERD, BE, and esophageal carcinoma. For these, as well as BMI and PPI, dates of first and last patient encounter where these were present were also sought. Patients' maximum-recorded BMI was used in assessing obesity status. These were categorized according to the World Health Organization classification: class I (30 kg/m^2^ ≤ BMI \< 35 kg/m^2^), class II (35 kg/m^2^ ≤ BMI \< 40 kg/m^2^), and class III (BMI ≥ 40 kg/m^2^) \[[@CR15]\].

A number of demographic details were also obtained including gender, age, and marital status. The prevalence of previously identified modifiable risk factors was also extracted. This included smoking, use of non-steroidal anti-inflammatories (NSAIDS), aspirin, corticosteroids, bisphosphonates, dopamine-2 (D2) antagonists, hormone replacement therapy (HRT), or oral contraceptive pill (OCP). The presence of other associated diseases was also recorded, such as hiatus hernia, gastritis/peptic ulcer disease (PUD), diabetes mellitus, hypertension, and hyperlipidemia. Coding data was also analyzed to determine which patients also received a prescription for histamine-2 (H2) antagonists for concurrent control of acid symptoms, while already on PPI therapy---termed "dual therapy."

Exclusion criteria included patients with a BMI ≥ 80 kg/m^2^ and/or aged ≥ 100 years old on first input into the CPRD to control for extreme variables that may account for incorrect coding.

Statistical Analysis {#Sec5}
--------------------

Demographic variables were analyzed using descriptive analysis. Univariate analysis was utilized to determine prognostic factors for progression onto GERD-related disorders from initial PPI commencement date. A logistic regression model was used to calculate odds ratios (ORs), with their associated 95% confidence interval (95% CI). Multivariate analysis was conducted of factors where the ORs had a *p* value \< 0.050 on univariate analysis. If one or fewer variables were found to have a *p* value \< 0.050, multivariate analysis would be conducted with variables which had a *p* value \< 0.100 to ensure that any potential prognostic factors were fully evaluated. Significance of multivariate analysis was determined using *p* value \< 0.050. Missing values were excluded from analysis. Statistical analysis was conducted using Statistical Package for Social Sciences (SPSS) \[IBM Statistics version 24 SPSS Inc., (Chicago, IL), USA\].

Results {#Sec6}
=======

One hundred sixty five thousand nine hundred twenty nine patients on the CPRD were identified with obesity on PPI treatment up until July 2017. The median follow-up time from date of starting PPI until database extraction or patient death was 119.0 months (range 11.3--1397.9 months). The median time between the first and last prescription for PPI therapy was 42.3 months (range 0.0--1397.2). Of this group, a number were diagnosed with GERD (*n* = 42,356), BE (*n* = 2119), and esophageal carcinoma (*n* = 60). Of these, some patients had GERD and BE (*n* = 934), GERD and esophageal carcinoma (*n* = 28), BE and esophageal carcinoma (*n* = 60), or all three diagnoses (*n* = 28). The demographic details of this cohort are detailed in full in Table [1](#Tab1){ref-type="table"}.Table 1Demographic dataPPIGERDBEECSubjects (*n*)165,92942,356211960Age53.2 ± 15.351.6 ± 14.358.7 ± 12.961.7 ± 12.2Sex Male57,775 (34.8%)13,622 (32.2%)1080 (51.0%)44 (73.3%) Female108,147 (65.2%)28,734 (67.8%)1039 (49.0%)16 (26.7%)BMI at first recording33.1 ± 6.232.6 ± 6.032.1 ± 5.032.4 ± 4.3BMI at last recording35.7 ± 6.535.6 ± 6.333.8 ± 5.730.5 ± 5.2Max BMI38.7 ± 6.638.5 ± 6.437.1 ± 5.636.9 ± 5.9BMI category Class I57,117 (34.4%)14,410 (34.0%)909 (42.9%)29 (48.3%) Class II52,052 (31.4%)13,727 (32.4%)701 (33.1%)21 (35.0%) Class III56,760 (34.2%)14,219 (33.6%)509 (24.0%)10 (16.7%)Hypertension34,369 (20.7%)9838 (23.2%)525 (24.8%)17 (28.3%)Diabetes mellitus47,082 (28.4%)11,766 (27.8%)648 (30.6%)21 (35.0%)Hyperlipidemia14,318 (8.6%)4327 (10.2%)260 (12.3%)7 (11.7%)Tobacco use42,433 (25.6%)10,881 (25.7%)422 (19.9%)12 (20.0%)Medication use Dual therapy20,726 (12.5%)8678 (20.5%)493 (23.3%)14 (23.3%) NSAIDs141,278 (85.1%)36,429 (86.0%)1685 (79.5%)47 (78.3%) Aspirin57,703 (52.9%)23,564 (55.6%)1388 (65.5%)45 (75.0%) HRT20,292 (12.2%)7051 (16.6%)219 (10.3%)2 (3.3%) OCP7885 (4.8%)2254 (5.3%)137 (6.5%)7 (11.7%) Steroids56,458 (34.0%)16,143 (38.1%)801 (37.8%)28 (46.7%) Bisphosphonates11,507 (6.9%)3211 (7.6%)233 (11.0%)9 (15.0%) D2 antagonist42,827 (25.8%)15,520 (36.6%)798 (37.7%)37 (61.7%)Gastritis/PUD8356 (5.0%)3247 (7.7%)200 (9.4%)3 (5.0%)Hiatus hernias18,931 (11.4%)8900 (11.7%)1146 (54.1%)29 (48.3%)*PPI* proton pump inhibitor, *GERD* gastroesophageal reflux disease, *BE* Barrett's esophagus, *EC* esophageal carcinoma, *BMI* body mass index (kg/m^2^), *Dual therapy* histamine-2 receptor antagonist use during PPI therapy, *NSAIDs* non-steroidal anti-inflammatories, *HRT* hormone replacement therapy, *OCP* oral contraceptive pill, *D2 antagonist* dopamine-2 receptor antagonist, *PUD* peptic ulcer disease

Prognostic Factors---GERD to BE {#Sec7}
-------------------------------

Table [2](#Tab2){ref-type="table"} outlines the variables that were evaluated for their effect on the likelihood of a patient with GERD developing BE in full. The following were all found to affect the development of BE: age ≥ 60 years old (OR = 1.425; *p* \< 0.001), male sex (OR = 1.926; *p* \< 0.001), class II obesity (OR = 0.47; *p* = 0.047), class III obesity (OR = 0.579; *p* \< 0.001), hyperlipidemia (OR = 1.355; *p* = 0.003), tobacco use (OR = 0.763; *p* = 0.003), dual therapy (OR = 1.563; *p* \< 0.001), NSAIDs (OR = 0.818; *p* = 0.043), aspirin (OR = 1.402; *p* \< 0.001), HRT (OR = 0.776; *p* = 0.014), bisphosphonates (OR = 1.3000; *p* = 0.026), D2 antagonists (OR = 1.419; *p* \< 0.001), gastritis/PUD (OR = 1.677; *p* \< 0.001), and hiatus hernias (OR = 6.12; *p* \< 0.001).Table 2Univariate analysis GERD to BEVariableNumberOR (95% CI)*p* valueAge \< 60 years old29,5621 ≥ 60 years old12,5991.425 (1.231--1.648)\< 0.001Sex Female28,6301 Male13,5311.926 (1.670--2.221)\< 0.001BMI category Class I14,3311 Class II13,6610.847 (0.719--0.998)0.047 Class III14,1690.579 (0.483--0.695)\< 0.001Hypertension Absent32,3691 Present97921.090 (0.926--1.282)0.299Diabetes mellitus Absent30,450 Present11,7110.977 (0.835--1.144)0.774Hyperlipidemia Absent37,8591 Present43021.355 (1.106--1.660)0.003Tobacco Non-smoker31,3231 Smoker10,8380.763 (0.639--0.912)0.003Dual therapy Not prescribed33,5361 Prescribed86251.563 (1.337--1.827)\< 0.001NSAIDs Not prescribed58871 Prescribed36,2740.818 (0.674--0.993)0.043Aspirin Not prescribed18,7261 Prescribed23,4351.402 (1.206--1.631)\< 0.001HRT Not prescribed35,1301 Prescribed70310.776 (0.634--0.949)0.014OCP Not prescribed39,9241 Prescribed22371.275 (0.966--1.681)0.086Steroids Not prescribed26,1001 Prescribed16,0611.116 (0.966--1.290)0.135Bisphosphonates Not prescribed38,9691 Prescribed31921.300 (1.032--1.638)0.026D2 antagonists Not prescribed26,7451 Prescribed15,4161.419 (1.230--1.637)\< 0.001Gastritis/PUD No diagnosis38,9341 Positive diagnosis32271.677 (1.357--2.072)\< 0.001Hiatus hernia No diagnosis33,3641 Positive diagnosis87976.107 (5.260--7.092)\< 0.001

Multivariate analysis confirmed that patients ≥ 60 years old (OR = 1.197; 95% CI 1.009--1.420; *p* = 0.039), male (OR = 2.209; 95% CI 1.846--2.644; *p* \< 0.001), on dual therapy (OR = 1.377; 95% CI 1.160--1.635; *p* \< 0.001), D2 antagonist use (OR = 1.241; 95% 1.057--1.458; *p* = 0.008), and having a hiatus hernia (OR = 6.772; 95% CI 1.410--32.529; *p* = 0.017) were at increased likelihood of developing BE.

Prognostic Factors---GERD to Esophageal Cancer {#Sec8}
----------------------------------------------

Table [3](#Tab3){ref-type="table"} displays all factors analyzed to determine their relationship between developing esophageal cancer following GERD in full. The following were all found to have an effect: age ≥ 60 years old (OR = 4.284; *p* = 0.002), male sex (OR = 3.204; *p* = 0.010), class III obesity (OR = 0.166; *p* = 0.019), aspirin (OR = 3.770; *p* = 0.028), and hiatus hernias (OR = 12.928; *p* \< 0.001).Table 3Univariate analysis GERD to esophageal carcinomaVariableNumberOR (95% CI)*p* valueAge \< 60 years old29,6561 ≥ 60 years old12,6744.284 (1.727--10.627)0.002Sex Female28,7211 Male13,6093.204 (1.320--7.774)0.01BMI category Class I14,4021 Class II13,7180.671 (0.262--1.720)0.406 Class III14,2100.166 (0.037--0.744)0.019Hypertension Absent32,5001 Present98300.856 (0.307--2.391)0.767Diabetes mellitus Absent30,5691 Present11,7611.285 (0.512--3.224)0.593Hyperlipidemia Absent38,0051 Present43250.879 (0.204--3.793)0.863Tobacco Non-smoker31,4581 Smoker10,8721.413 (0.475--4.205)0.534Dual therapy Not prescribed33,6571 Prescribed86731.312 (0.497--3.462)0.583NSAIDs Not prescribed59221 Prescribed36,4080.464 (0.169--1.278)0.138Aspirin Not prescribed18,7791 Prescribed23,5513.977 (1.164--13.592)0.028HRT Not prescribed35,2811 Prescribed70480.036 (0.000--4.754)0.182OCP Not prescribed40,0781 Prescribed22521.825 (0.423--7.870)0.42Steroids Not prescribed26,1971 Prescribed16,1331.874 (0.776--4.525)0.162Bisphosphonates Not prescribed39,1191 Prescribed32111.884 (0.551--6.438)0.312D2 antagonists Not prescribed26,8241 Prescribed15,5061.642 (0.693--3.890)0.260Gastritis/PUD No diagnosis39,0831 Positive diagnosis32470.575 (0.077--4.294)0.589Hiatus hernia No diagnosis33,4361 Positive diagnosis889412.928 (4.320--38.690)\< 0.001

Multivariate analysis found age (OR = 2.831; 95% CI 1.100--7.284; *p* = 0.031), male sex (OR = 3.954; 95% CI 1.603--9.755; *p* = 0.003), and hiatus hernias (OR = 12.170; 95% CI 4.044--36.627; *p* \< 0.001) to all be associated with increased probability of developing esophageal cancer following GERD.

Prognostic Factors---BE to Esophageal Cancer {#Sec9}
--------------------------------------------

Table [4](#Tab4){ref-type="table"} details all variables investigated that might influence rates of esophageal cancer in BE patients. Class III obesity reduced the probability of patients developing esophageal cancer compared to class I obesity (OR = 0.345; *p* = 0.019). D2 antagonist use was found to be positively associated with increased increase of esophageal carcinoma (OR = 2.927; *p* \< 0.001).Table 4Univariate analysis BE to esophageal carcinomaVariableNumberOR (95% CI)*p* valueAge \< 60 years old11111 ≥ 60 years old10001.375 (0.776--2.439)0.276Sex Female10341 Male10771.557 (0.744--3.261)0.24BMI category Class I9071 Class II6981.727 (0.895--3.331)0.103 Class III5060.345 (0.142--0.843)0.019Hypertension Absent15891 Present5221.677 (0.888--3.168)0.111Diabetes mellitus Absent14681 Present6430.586 (0.315--1.090)0.091Hyperlipidemia Absent18511 Present2600.848 (0.379--1.896)0.688Tobacco Non-smoker16921 Smoker4191.880 (0.861--4.102)0.113Dual therapy Not prescribed16181 Prescribed4931.059 (0.557--2.013)0.861NSAIDs Not prescribed4321 Prescribed16790.961 (0.477--1.935)0.91Aspirin Not prescribed7301 Prescribed13810.978 (0.517--1.849)0.946HRT Not prescribed18921 Prescribed2190.655 (0.156--2.749)0.563OCP Not prescribed19761 Prescribed1350.603 (0.212--1.718)0.344Steroids Not prescribed13131 Prescribed7980.743 (0.406--1.361)0.336Bisphosphanates Not prescribed18781 Prescribed2331.656 (0.796--3.446)0.177D2 antagonists Not prescribed13161 Prescribed7952.927 (1.631--5.254)\< 0.001Gastritis/PUD No diagnosis19111 Positive diagnosis2000.509 (0.159--1.641)0.258Hiatus hernia No diagnosis9681 Positive diagnosis11430.602 (0.343--1.057)0.077

Multivariate analysis found that D2 antagonist use was the only determinant factor that was associated with increased development from BE to esophageal carcinoma (OR = 2.588; 95% CI 1.426--4.695; *p* = 0.002).

Discussion {#Sec10}
==========

This large-scale population analysis of obese patients on PPIs has elucidated some potential factors that may be associated with progression of GERD-related diseases. Despite PPI use, risk factors such as male sex, age, H2 antagonists, D2 antagonists, and hiatus hernias were additionally identified within this specific group of patients. Interestingly, no correlation was found between obesity beyond ≥ 35 kg/m^2^ and risk of progression to BE or esophageal carcinoma. Beyond this, the results of this study also indicate that the associated metabolic complications of obesity (diabetes, hypertension, and hyperlipidemia) are not associated with worsening reflux disease and that any effect of obesity is independent to this.

For patients with GERD, increased levels of obesity, notably class II and class II obesity compared to class I obesity, were not found to affect the rate of developing BE or esophageal carcinoma on multivariate analysis (*p* \> 0.050). This is contradictory to a significant body of evidence that has linked obesity to increasing incidence of BE and esophageal carcinoma \[[@CR16], [@CR17]\]. However, the majority of previous evidence compares obese patients against normal weight controls, without subgroup analysis between obesity categories \[[@CR6], [@CR18]\]. Obesity is proposed to increase intra-abdominal pressure via abdominal obesity, resulting in increased reflux of gastric contents resulting in inflammation and potential progression to dysplasia and metaplasia \[[@CR19]\]. Two mechanisms could be behind the lack of correlation seen. Firstly, increasing abdominal obesity, beyond a certain threshold, does not equate to increased gastric reflux. Secondly, PPI therapy may negate the negative effects of abdominal obesity; evaluation of PPI treatment by Sharma et al. found that reflux resolution is similar across BMI categories during PPI treatment \[[@CR12]\]. A retrospective analysis additionally found that PPI therapy in obese patients is effective for resolution of gastric reflux \[[@CR20]\]. This suggests that PPI therapy in this population may negate the potential impact of higher abdominal obesity in progression from GERD to BE or esophageal carcinoma. This highlights the importance of starting PPI treatment in patients with high BMI and reflux symptoms, or diagnosed with GERD-related disorders. These results may also be explained by a different hypothesis, that GERD is the intermediate step between obesity and the BE and esophageal carcinoma pathway. Subsequently, increasing obesity does not increase the risk of further progression but does increase the overall risk of patients with grade II/III obesity by increasing their initial risk of GERD. Therefore, PPI therapy will be important, in addition to seeking effective means to reduce weight.

An interesting factor highlighted in this analysis is that patients who required concurrent therapy with H2 antagonists were at increased risk from progression from GERD to BE (OR = 1.377). Dual therapy with both H2 antagonists and PPIs has been previously demonstrated to reduce acid reflux \[[@CR21]\]. However, no studies have evaluated these patients over a prolonged follow-up period. These patients by definition have reflux disease that is refractory to PPI monotherapy. This suggests that the degree of reflux from which they suffer is worse either symptomatically, pathologically, or both. This long-term follow-up highlights that these patients are at increased risk of developing BE. This therefore indicates that while initiating dual therapy is beneficial for reducing esophageal acidity, these patients need closer follow-up to ensure compliance with medication and resolution of reflux. This is further highlighted by the fact that patients who were started on D2 antagonists, such as metoclopramide or domperidone, were also at increased risk of developing BE (OR = 1.241) and then subsequently esophageal carcinoma (OR = 2.588). D2 antagonists can be used to increase gastric motility to help reduce esophageal acidity and again may indicate more severe reflux therefore increasing risk of serious GERD-related conditions. This data, however, is confounded by its more common use as an anti-emetic, particularly in cancer patients. All together, these pieces of evidence do suggest that increased follow-up of patients with PPI-refractory reflux is important to reduce progression to metaplasia and subsequently dysplasia.

Hiatus hernia was shown to be associated with the greatest risk of BE (OR = 6.772) and esophageal carcinoma (OR = 12.170). Hiatus hernias have previously been shown to increase the risk of these conditions via increasing reflux of gastric contents into the esophagus \[[@CR22]\]. Gastric fundoplication is effective in significantly reducing acid reflux in an obese cohort \[[@CR23]\]. It provides improved resolution of reflux compared to PPI therapy for GERD with or without an associated hiatus hernia \[[@CR24], [@CR25]\]. Gastric bypass operations for morbid obesity have also been shown to reduce acid reflux, in addition to reducing BMI and metabolic conditions \[[@CR26]\]. Future studies are required to evaluate whether a hybrid hiatus hernia repair and gastric bypass would also be a suitable therapeutic modality. In contrast to gastric bypasses, sleeve gastrectomy can aggravate GERD postoperatively \[[@CR27]\]. Surgical therapy has been shown to improve patient quality of life, induce regression of metaplasia, and reduce progression to esophageal carcinoma over long-term evaluation \[[@CR28]\]. It is therefore important that applicable patients are able to access appropriate surgical therapy to alleviate the consequences of raised gastric reflux. This includes patients with a hiatal hernia and those who fail PPI therapy. It is also important that candidates for bariatric surgery with GERD are advised to avoid sleeve gastrectomy as this may worsen their symptoms.

This study, despite benefiting from the analysis of a large population, is still subject to limitations. Any analysis from a database is reliant upon correct and timely coding of all clinical parameters. This is unable to be confirmed on an individual patient basis due to the inability to access original patient files. Subsequently, this may result in a discrepancy between clinical codes and actual patient disease or medication. Moreover, the length of follow-up within this study, despite a median of 119.0 months, may not be sufficient to capture all cases of BE or esophageal carcinoma within this cohort as the progression of both these diseases from GERD is typically over the course of many years. However, any misclassification or lack of capture would bias the results towards a non-significant difference. Additionally, selection bias is minimized as all included patients are derived from a database that has been previously validated as representative of the national population \[[@CR13]\]. While the CPRD gives a reliable estimate of patient BMI across many years, factors such as waist circumference, which are infrequently measured, are difficult to include in analyses. Additionally, compliance with medication cannot be assessed reliably. Finally, due to clinical coding, it is not possible to evaluate all possible risk factors that may play a role in the pathogenesis of GERD-related conditions. The two most notable of these are ABO blood group and alcohol consumption, which have both been shown to be associated with said conditions \[[@CR29], [@CR30]\]. These are 2 variables that are not reliably assessed frequently enough in general practice clinics to be used with any certainty in this analysis. Despite this, analysis of the CPRD is still the most reliable way of conducting a retrospective analysis of a population size of this magnitude in the UK.

Conclusions {#Sec11}
-----------

This large population analysis of obese patients on PPI therapy has demonstrated that increasing BMI beyond an obese baseline does not significantly contribute to the development of BE and or esophageal carcinoma. Males, older patients, persons who fail PPI monotherapy, and those with hiatus hernias are at most increased risk of developing BE and carcinoma. These are important factors to consider when deciding which patients require most intensive follow-up or require appropriate interventions such as anti-reflux surgery or starting dual pharmacological therapy.
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